Cenerimod(一种鞘氨醇-1-磷酸受体调节剂)对比安慰剂治疗中重度系统性红斑狼疮患者(CARE):一项国际、双盲、随机、安慰剂对照的2期试验
CARE是一项国际双盲随机安慰剂对照2期试验,纳入427例中重度SLE患者,评估四种剂量cenerimod对比安慰剂的疗效与安全性。主要终点(第6个月mSLEDAI-2K评分较基线变化)未达到,仅4.0 mg组差异vs安慰剂-1.19(95%CI -2.25至-0.12;p=0.029)但未通过多重性校正。Cenerimod耐受性良好,4.0 mg正在两项3期试验中研究。
要点
- 主要终点未达到:第6个月mSLEDAI-2K评分较基线变化,各cenerimod剂量组与安慰剂组差异均未通过预设多重性校正。
- 4.0 mg组第6个月mSLEDAI-2K评分较基线变化-4.04(95%CI -4.79至-3.28),与安慰剂差异-1.19(95%CI -2.25至-0.12;p=0.029)。
- 截至12个月治疗中出现的不良事件在各组间无明确治疗相关或剂量相关模式;治疗中出现淋巴细胞减少症在4.0 mg组为12/84(14%)。
核心结论
- 主要终点未达到;cenerimod在12个月内耐受性良好;4.0 mg正在两项进行中的3期试验(NCT05648500、NCT05672576)中研究用于SLE治疗。
研究设计与样本
- CARE为双盲、随机、安慰剂对照2期试验,纳入18-75岁中重度SLE成人(mSLEDAI-2K评分至少6/105),来自22个国家189家医院、专科中心和门诊。
- 参与者按1:1:1:1:1随机分配至每日口服cenerimod 0.5 mg、1.0 mg、2.0 mg、4.0 mg或安慰剂,联合稳定背景SLE治疗,随访12个月。
- 6个月后,4.0 mg组参与者再次按1:1随机分配至cenerimod 2.0 mg或安慰剂,继续6个月。
- 主要终点为第6个月mSLEDAI-2K评分较基线变化,在全分析集(所有随机分配参与者)中评估;安全性分析纳入所有至少接受一剂研究治疗的参与者。
主要发现
- 2018年12月21日至2022年8月25日筛选810例患者,427例随机分配至cenerimod 0.5 mg(n=85)、1.0 mg(n=85)、2.0 mg(n=86)、4.0 mg(n=85)或安慰剂(n=86)。
- 中位年龄42岁(IQR 33-51),427例中406例(95%)为女性、21例(5%)为男性,337例(79%)为白人。
- 第6个月mSLEDAI-2K评分较基线最小二乘均值变化:安慰剂组-2.85(95%CI -3.60至-2.10);0.5 mg组-3.24(-3.98至-2.49;vs安慰剂差异-0.39[95%CI -1.45至0.68];p=0.47);1.0 mg组-3.41(-4.16至-2.67;vs安慰剂差异-0.57[-1.62至0.49];p=0.29);2.0 mg组-2.84(-3.58至-2.09;vs安慰剂差异0.01[-1.05至1.08];p=0.98);4.0 mg组-4.04(-4.79至-3.28;vs安慰剂差异-1.19[-2.25至-0.12];p=0.029)。
- 截至12个月治疗中出现的不良事件在各组间无明确治疗相关或剂量相关模式。
- 第6个月治疗中出现淋巴细胞减少症:0.5 mg组1/85(1%)、1.0 mg组5/85(6%)、2.0 mg组9/86(10%)、4.0 mg组12/84(14%)、安慰剂组0例。
关键数值与推荐
- 主要终点未达到:预设分层检验策略下,各cenerimod剂量组第6个月mSLEDAI-2K评分较基线变化与安慰剂相比未通过多重性校正。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要终点未达到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sphingosine-1-phosphate (S1P) is a signalling molecule that has an inhibitory role in atherosclerosis, inflammation, cell proliferation, and immunity. Cenerimod is a selective S1P1 receptor modulator under investigation for the treatment of systemic lupus erythematosus (SLE). We aimed to determine the efficacy, safety, and tolerability of four doses of cenerimod in adults with moderate-to-severe SLE receiving standard of care background therapy. METHODS: CARE was a double-blind, randomised, placebo-controlled, phase 2 trial, in adults (aged 18-75 years) with moderate-to-severe SLE (a score of at least 6 out of 105 on the SLE disease activity index-2000, modified to exclude leukopenia [mSLEDAI-2K] score). Participants were recruited from 189 hospitals, specialist centres, and outpatient clinics in 22 countries in Asia Pacific, Latin America, Europe, and the USA. Participants were randomly assigned (1:1:1:1:1), using an interactive response technology via balanced block randomisation (block size of 5) and stratified by oral glucocorticoid dose at randomisation and disease activity at screening, to once-daily oral cenerimod at 0·5 mg, 1·0 mg, 2·0 mg, or 4·0 mg or placebo, in addition to stable background SLE therapy, and followed up for 12 months. After 6 months, participants assigned to cenerimod 4·0 mg were randomly assigned again (1:1) to either cenerimod 2.0 mg or placebo for a further 6 months. The primary endpoint was change from baseline to month 6 in mSLEDAI-2K score, assessed in all participants randomly assigned to treatment (full analysis set). To meet the primary endpoint, the doses had to show a significant improvement over placebo, when adjusting for multiplicity, considering the hierarchical testing strategy, per a prespecified plan. Safety analyses included all participants who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT03742037, and is complete. FINDINGS: Between Dec 21, 2018, and Aug 25, 2022, 810 patients were screened and 427 were randomly assigned to 0·5 mg (n=85), 1·0 mg (n=85), 2·0 mg (n=86), and 4·0 mg (n=85) cenerimod or placebo (n=86). Median age was 42 years (IQR 33-51), 406 (95%) of 427 participants were women, 21 (5%) were men, and 337 (79%) were White. At month 6, the least squares mean change from baseline in mSLEDAI-2K score was -2·85 (95% CI -3·60 to -2·10) for the placebo group and -3·24 (-3·98 to -2·49; difference vs placebo -0·39 [95% CI -1·45 to 0·68]; p=0·47) for the cenerimod 0·5 mg group, -3·41 (-4·16 to -2·67; difference vs placebo -0·57 [-1·62 to 0·49]; p=0·29) for the 1·0 mg group, -2·84 (-3·58 to -2·09; difference vs placebo 0·01 [-1·05 to 1·08]; p=0·98) for the 2·0 mg group, and -4·04 (-4·79 to -3·28; difference vs placebo -1·19 [-2·25 to -0·12]; p=0·029) for the 4·0 mg group; hence, the primary endpoint was not met. Treatment-emergent adverse events up to 12 months had no clear treatment-related or dose-related pattern across the groups. At month 6, treatment-emergent lymphopenia was reported in one (1%) of 85 patients who received cenerimod 0·5 mg, five (6%) of 85 patients who received 1·0 mg, nine (10%) of 86 patients who received 2·0 mg, 12 (14%) of 84 patients who received 4·0 mg, and no patients who received placebo. Two deaths due to adverse events occurred (both in the cenerimod 1·0 mg group; one due to acute coronary syndrome and the other due to upper gastrointestinal haemorrhage), and were determined to be unrelated to study treatment. INTERPRETATION: The primary endpoint was not met. Cenerimod was well tolerated over 12 months. Cenerimod 4·0 mg is being investigated for the treatment of SLE in two ongoing phase 3 trials (NCT05648500, NCT05672576). FUNDING: Idorsia Pharmaceuticals.
引用
- Askanase AD, D'Cruz D, Kalunian K, et al. Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2024. PMID: 39586304. doi:10.1016/S2665-9913(24)00246-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。